drugset / Trial / NCT04346667
Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds
Phase 4
Terminated
125 enrolled
Government of Punjab, Specialized Healthcare and Medical Education Department
Forman Christian College, Pakistan · collabHarvard School of Public Health (HSPH) · collabMayo Hospital Lahore · collabPakistan Kidney and Liver Institute · collabServices Institute of Medical Sciences, Pakistan · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.
Timeline
- Start
- 2020-04-14
- Primary completion
- 2020-08-23
- Completion
- 2020-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Chloroquine | Small molecule | 500 mg | — |
| Comparator | Hydroxychloroquine | Small molecule | 200 mg | — |
| Comparator | Hydroxychloroquine | Small molecule | 400 mg | — |